第一财经·2025-11-07 15:51Core Insights - Trump announced agreements with pharmaceutical giants Novo Nordisk and Eli Lilly to reduce the prices of their popular weight loss drugs [3][4] - Novo Nordisk plans to set the monthly price for the lowest dose of Wegovy at $149, expanding this pricing strategy to all patient-facing products [3] - Eli Lilly's lowest dose of Zepbound will start at $299, with the highest dose at $449, approximately $50 lower than current direct-to-patient prices [3] Pricing Strategies - Novo Nordisk will lower prices for its injectable drugs, including Wegovy and Ozempic, under Medicare Part D, Medicaid, and self-pay channels [3] - Eli Lilly's new oral weight loss drug, Orforglipron, will also have a minimum dose price of $149, pending federal approval [3] Market Impact - The U.S. Department of Health and Human Services Secretary stated that this initiative will significantly impact all citizens, including those without insurance, by providing equal access to GLP-1 drugs [4] - It is projected that by next year, the cumulative weight loss among Americans could reach 125 million pounds (approximately 56 million kilograms) due to increased accessibility to weight loss medications [4]